We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+7.87%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
–
AUM
$9.04B
AUM Growth
+$2.19B
Cap. Flow
+$1.88B
Cap. Flow %
20.78%
Top 10 Hldgs %
34.88%
Holding
3,092
New
1,032
Increased
581
Reduced
587
Closed
820

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$435M
2
AMZN icon
Amazon
AMZN
+$334M
3
MRNA icon
Moderna
MRNA
+$53.9M
4
LIN icon
Linde
LIN
+$44.2M
5
DTE icon
DTE Energy
DTE
+$43.5M

Top Sells

Rank Stock Value
1
IWD icon
iShares Russell 1000 Value ETF
IWD
+$63.6M
2
CMCSA icon
Comcast
CMCSA
+$39.7M
3
EVRG icon
Evergy
EVRG
+$38.5M
4
PEG icon
Public Service Enterprise Group
PEG
+$38.4M
5
TECH icon
Bio-Techne
TECH
+$30.9M

Sector Composition

Rank Sector Weight
1 Technology 15.37%
2 Consumer Discretionary 10.36%
3 Financials 7.14%
4 Industrials 6.8%
5 Healthcare 6.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
2251
DELISTED
Genocea Biosciences, Inc.
GNCA
$26K ﹤0.01%
11,131
-100
-0.9% -$241
WHWK
2252
Whitehawk Therapeutics
WHWK
$278M
$25K ﹤0.01%
+1,001
New +$22.9K
QTS
2253
DELISTED
QTS REALTY TRUST, INC.
QTS
$23K ﹤0.01%
+293
New +$19.9K
TRVN
2254
DELISTED
Trevena, Inc.
TRVN
$19K ﹤0.01%
18
-637
-97% -$714K
CLRB icon
2255
Cellectar Biosciences
CLRB
$23.8M
$17K ﹤0.01%
48
-25
-34% -$10.8K
ACGN
2256
DELISTED
Aceragen Inc
ACGN
$17K ﹤0.01%
820
-910
-53% -$18.3K
PULM icon
2257
Pulmatrix
PULM
$5.66M
$15K ﹤0.01%
+730
New +$14.8K
VPU
2258
Vanguard Utilities ETF
VPU
$8.35B
$14K ﹤0.01%
+100
New +$14.3K
HHLA.WS
2259
DELISTED
HH&L Acquisition Co. Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50
HHLA.WS
$14K ﹤0.01%
+16,100
New +$12K
SLNO
2260
DELISTED
Soleno Therapeutics
SLNO
$13K ﹤0.01%
734
-52
-7% -$879
VRS
2261
DELISTED
Verso Corporation
VRS
$6K ﹤0.01%
+342
New +$5.64K
FDVV icon
2262
Fidelity High Dividend ETF
FDVV
$10.4B
$4K ﹤0.01%
+100
New +$3.74K
FUTY icon
2263
Fidelity MSCI Utilities Index ETF
FUTY
$2.27B
$4K ﹤0.01%
+100
New +$4.24K
UA icon
2264
Under Armour Class C
UA
$2.25B
$4K ﹤0.01%
+222
New +$4.18K
BATRA icon
2265
Atlanta Braves Holdings Series A
BATRA
$3.68B
$1K ﹤0.01%
+18
New +$502
FWONA icon
2266
Liberty Media Series A
FWONA
$24.6B
$1K ﹤0.01%
33
-883
-96% -$34.2K
AAON icon
2267
Aaon
AAON
$6.27B
– –
-6,897
Closed -$322K
AAP icon
2268
Advance Auto Parts
AAP
$2.63B
– –
-21,778
Closed -$4M
ABT icon
2269
Abbott
ABT
$202B
– –
-39,443
Closed -$4.73M
ABUS icon
2270
Arbutus Biopharma
ABUS
$1.03B
– –
-160,048
Closed -$533K
ACA icon
2271
Arcosa
ACA
$7.13B
– –
-20,020
Closed -$1.3M
ACGL icon
2272
Arch Capital
ACGL
$34.5B
– –
-49,974
Closed -$1.92M
ACET icon
2273
Adicet Bio
ACET
$83.3M
– –
-4,480
Closed -$938K
ACI icon
2274
Albertsons Companies
ACI
$6.12B
– –
-24,503
Closed -$467K
ACIU icon
2275
AC Immune
ACIU
$284M
– –
-13,226
Closed -$101K
89 90
91
92 93

Similar funds

FGP
Freestone Grove Partners San Francisco, California $15.6B AUM 27.39% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
AA
Acorns Advisers Irvine, California $15.3B AUM 18.32% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $15.8B AUM 1.29% 1-Year Est. Return
NMIFOAC
National Mutual Insurance Federation of Agricultural Cooperatives Tokyo, Japan, Japan $15.3B AUM 24.71% 1-Year Est. Return

Michael Gelband's Q2 2021 Portfolio in Review

As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.

  • Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
  • Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
  • Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
  • Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
  • Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
  • Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
  • Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.